Relapses after autologous stem cell transplants for hematopoietic malignancies are frequent and post-transplant infections continue to cause significant post-transplant morbidity and even mortality. The post-transplant period is typically characterized by low lymphocyte counts and impaired immune cell function. Early restoration of immune function may contribute to better disease control and enhance protection from infections. Indeed the attainment of a 'minimal residual disease' status following high-dose therapy makes the early post-transplant period ideal for the introduction of antitumor immunotherapy. Attempts to generate immunity against tumor and microbial antigens after autotransplantation have included vaccinations, T cell infusions (both resting and activated) and combinations of vaccinations and adoptive T cell infusions. One successful strategy for generating robust immune responses against microbial antigens was the combination of pre and posttransplant immunizations along with an early (posttransplant) infusion of in vivo vaccine-primed and ex vivo co-stimulated autologous T cells. Whether this or similar strategies will lead to the generation of effective antitumor immunity is unknown. The lessons gained from efforts to rebuild immune system function in the setting of autotransplantation may also be applicable to the problem of restoring immunity in other immunodeficient groups such as patients with cancer or HIV disease and the elderly. 
Problem of post-transplant immunodepletion
High-dose therapy followed by autologous stem cell transplantation has significantly improved the disease-free and overall survival for patients with relapsed or refractory lymphoma and newly diagnosed myeloma. [1] [2] [3] [4] [5] [6] However, relapses of lymphoma are frequent particularly among patients with chemorefractory disease. In addition, cures of myeloma are rare due to the lack of an effective antitumor immune response to eradicate minimal residual disease. In theory, the early post-transplant phase should be an ideal setting for antitumor immune responses to operate given the lower tumor burden. Furthermore, animal models suggest that the early post-transplant period may be especially conducive for the development of effective antitumor immune responses. [7] [8] [9] Unfortunately, the same intensive therapy which provides the opportunity for successful tumor immunotherapy also depletes the immune cells and compromises the immune cell function necessary to execute it. In addition to compromising the ability of autograft recipients to mount effective antitumor immune responses, post-transplant immunodeficiencies increase the risk for serious infections from varicella-zoster virus (VZV), cytomegalovirus (CMV) and Streptococcus pneumoniae.
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Indeed, the 23-valent pneumococcal polysaccharide vaccine is recommended by the American Society for Blood and Marrow Transplantation for all autotransplant patients at 1 and 2 years post-transplant because earlier immunizations are ineffective. 12 Even then, immune responses to this vaccine are limited with only 19% of patients achieving potentially protective antibody levels at 2 years post transplant. 13 A range of immunodeficiencies have been described following high-dose therapy. Recognizing that variability exists in the pattern and severity of immunodepletion depending on the type of regimen that is employed, a summary of these post-transplant immune system deficiencies is presented in Table 1. 14-18 It is apparent from this table that numeric and functional recovery of CD4 þ T cells is markedly impaired and delayed compared to other immune parameters. CD8 þ T cell recovery is very rapid due primarily to expansion of the CD8 þ CD57 þ and CD8 þ CD28À subsets, leading to prolonged inversion of the CD4/CD8 ratios. 14 The mechanisms by which the profound CD4 þ T cell deficiency develops post transplant are not fully understood but probably involve agedependent thymic dysfunction. Indeed, CD4 þ T cell recovery is enhanced among patients with thymic enlargement and younger age.
14 Furthermore, post-transplant recovery of CD4 þ T cell numbers and function appears to be accelerated in children, as 60% of pediatric autotransplant recipients reached CD4 þ counts 4200/ml and nearly two-thirds exhibited normal T cell proliferative responses to phytohemagglutinin (PHA) and alloantigens by 6 months post transplant. 19 A few studies using CD34 þ selection of stem cells (T cells depleted by negative selection) also show further delays in CD4 þ T cell recovery (but not CD8 þ recovery) among recipients of CD34 þ -selected grafts compared to recipients of unselected grafts. 20 Importantly, the rate of CD4 þ T cell recovery correlates inversely with the incidence of posttransplant opportunistic infections in both the autologous and allogeneic settings. [19] [20] [21] Relapses of disease and the use of post-transplant consolidative or maintenance therapies will certainly further compromise immune recovery and increase susceptibility to infections. However, even among patients who were in complete remission for 4-10 years after autologous transplants about one-third lacked protective immunity to diphtheria and poliovirus and nearly two-thirds lacked protection against S. pneumoniae.
22
Furthermore, single vaccinations to diphtheria and poliovirus elicited minimal responses (compared to healthy controls) although protective levels developed after a series of 3 vaccinations. Administration of the 23-valent pneumococcal vaccine to patients led to protective antibody levels in only 32-41% of patients depending on the serotype analyzed as compared to 80-94% of healthy controls. 22 When CD4 þ T cells do show recovery during the first year after high-dose therapy, it is mainly due to peripheral expansion of the limited number of mature memory cells (CD45RO þ CD4 þ ) which remain after chemotherapy or which may be reinfused with the stem cell graft; generation of CD45RA þ cells by thymic production appears to play a very minor role. 15 Furthermore, when these expanded CD45RO þ cells are stimulated in vitro by mitogens, susceptibility to apoptosis is significantly increased compared to normal donors. IL-7 appears to play a critical role in the homeostatic peripheral expansion (HPE), which occurs in lymphopenic patients after transplantation. 23 As a result of HPE of residual memory cells, the T cell repertoire generally becomes restricted after high-dose therapy as demonstrated by T cell receptor spectratyping, which in turn limits the ability of the immune system to respond to new antigens. However, thymic enlargement and functional recovery does occur in an age-dependent fashion in about one-third of adult autograft recipients (mainly those less than age 50 years) and correlates with recovery of naı¨ve (CD4 þ CD45RA þ CD62L þ ) T cells, restoration of T cell receptor diversity, increased levels of T-cell receptor excision circle-bearing cells (TRECs) and ultimately longterm recovery of CD4 þ T-cell numbers and function. 24 Strategies to restore immune function are clearly needed in order to reduce the incidence of post-transplant morbidity and mortality from early or late opportunistic infections (e.g. VZV, CMV) and to enhance protection against common pathogens (e.g. S. pneumoniae, influenza A). 10, 11, 25 In addition, retrospective studies suggest that better clinical outcomes from autotransplantation for myeloma and lymphoma may be associated with more rapid post-transplant lymphocyte recovery. 26, 27 Efforts to augment immune responses after high-dose therapy have been chiefly based upon post-transplant (or pre-and posttransplant) vaccinations of microbial antigens or putative tumor antigens -the latter with dendritic cells (DCs) to optimize antigen presentation. Recent work has also focused on strategies to augment immune cell recovery after transplant through adoptive transfer of ex vivo expanded and costimulated autologous T cells. Table 2 lists some of the limitations and problems associated with these post-autograft vaccine studies.
Vaccinations against infectious diseases
Selected studies of antimicrobial vaccines are summarized in Table 3 . 13, 22, [28] [29] [30] [31] With the caveat that most of these studies included relatively small numbers of patients who were heterogeneous with respect to prior treatment, disease type and transplant therapy, several conclusions may be warranted: first, while immunizations with the pneumococcal polysaccharide vaccine at 12 and 24 months posttransplant are American Society for Blood and Marrow 
References: [14] [15] [16] [17] [18] . NML ¼ Reached normal range or not significantly different from pre-transplant baseline; k ¼ Mild reduction (generally o25% below pre-transplant baseline); kk ¼ Moderate reduction (generally 25-75% below pre-transplant baseline); kkk ¼ Severe reduction (generally 475% below pre-transplant baseline).
Transplantation (ASBMT) recommended, the response rates are very low with less than one-third of patients achieving protective antibody levels when responses to multiple serotypes are analyzed. Second, antibody responses to the pneumococcal conjugate vaccine (PCV-7) may be higher especially when multiple immunizations are given. In particular, vaccination prior to stem cell collection may be critical for optimal antibody responses. 29 The currently licensed pneumococcal conjugate vaccine contains seven oligosaccharide antigens (for serotypes 4, 6B, 9V,14, 18C, 19F, 23F) conjugated to a carrier protein (CRM 197) , which is a nontoxic derivative of diphtheria toxin and is licensed for use in newborns and infants who do not normally respond to the polysaccharide vaccine. 32 The enhanced immunogenicity of the conjugate vaccine is thought to be related to induction of T cell help by the carrier protein. A randomized trial using a heat-inactivated formulation of the VZV vaccine demonstrated higher T cell proliferative responses and a significantly lower rate of VZV infection among autotransplant patients who were vaccinated 30 days before transplant and at days 30, 60 and 90 days post-transplant. 31 This study also emphasizes the importance of delivering pre-transplant vaccinations combined with multiple post-transplant booster vaccinations. In addition, this positive study highlights one of the aforementioned problems in the field: the standard VZV vaccine is derived from a live-attenuated strain which might be unsuitable for early post-transplant administration, whereas the heat-inactivated formulation is not commercially available. Third, although robust antibody responses to recall antigens such as poliovirus and tetanus toxoid develop in most patients after three immunizations, responses to single immunizations of influenza or poliovirus/tetanus toxoid are generally poor and infrequent. Finally, the use of peripheral blood stem cell grafts (which contain about 10-fold higher levels of T cells) may be associated with better responses to microbial vaccines than marrow grafts, although there are no randomized studies to support this notion. 30 
Tumor vaccination strategies
The process of generating or restoring immunity to tumor targets after autotransplantation is clearly more difficult than the process of restoring immunity to infectious agents. First, as most tumor antigens are identical to or derived from self-antigens, normal T cell ontogeny ('negative' and 'positive' thymic selection) results in deletion or weakening of potentially tumor-reactive T cell populations; second, most tumors have developed mechanisms for evading or specifically downregulating host antitumor immune responses, a phenomenon known as 'immunological tolerance'. The mechanisms whereby tumors escape from host immune responses is beyond the scope of this review (see Mapara and Sykes 33 ) . A list of these mechanisms along with potential strategies for countering them is provided in Table 4 . It is apparent that some of these mechanisms of immune evasion may be at least partially circumvented by high-dose chemotherapy and autotransplantation through reductions in tumor burden and temporary clearance of regulatory T cell populations. Indeed animal models suggest that the early post-transplant period is well-suited to development of effective antitumor immune responses. [7] [8] [9] The clinical efficacy of a post-transplant tumor vaccination strategy will likely depend on at least three factors: (1) identification of a suitable tumor antigen(s) that may be a selectively expressed mutant protein ('tumor-specific antigen') or an upregulated normal cellular protein ('tumorassociated antigen') in the target tumor; (2) formulation of the tumor antigen(s) into a vaccine for optimal antigen presentation to T cells; (3) presence of adequate numbers of functional T cells that can respond to the tumor vaccine and generate immunologic memory. In Table 5 are summarized selected clinical trials that have studied the use of potential tumor vaccines in the postautotransplant setting. [34] [35] [36] [37] [38] Most of these earlier trials included small numbers of patients and utilized putative tumor vaccines that were conjugated to keyhole limpet hemocyanin (KLH), although at least one trial utilized idiotype-pulsed DCs after autotransplants for myeloma. 34 In these studies, robust anti-KLH responses developed in the majority of patients after multiple immunizations, although another study showed that antibody and T cell responses following a single post-transplant immunization of KLH were very poor compared to normal controls and patients with advanced cancer even up to 16 months post transplant. 39 The frequency and levels of antibody and cellular immune responses to the vaccines were variable and could not be clearly correlated to clinical response nor outcome. A range of other putative tumor vaccines that could be amenable to post-transplant administration have shown promise in pre-clinical or early clinical development (see Table 6 ). [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Many candidate vaccines under investigation are peptides that are selected for binding affinity to common HLA class II or class I alleles (usually HLA-A2). Although some candidate tumor vaccine antigens and peptides have been selected for study because affected patients have pre-existing T cell responses to those specific antigens, these T cells are often dysfunctional and fail to Rebuilding immunity after autotransplantation AP Rapoport exhibit cytotoxicity as a result of tumor-induced tolerance mechanisms. Furthermore, immune responses to highaffinity HLA-binding peptides may be absent on the basis of negative selection during normal T cell development in the thymus. Thus, recent efforts have focused on the identification of putative tumor antigens that may be upregulated in malignant cells yet may be 'ignored' by the immune system. These antigens are tested for immunoreactivity in normal or tumor-bearing hosts and 'subdominant' or 'cryptic' epitopes with lower native affinity for HLA alleles are selected for further study in order to bypass central (thymic) tolerance mechanisms. [44] [45] [46] [47] [48] 51 In some cases, the HLA-binding affinity and immunogenicity of the peptides derived from these cryptic epitopes may be augmented by minor amino-acid modifications to form 'heteroclitical' peptides. 51 However, the use of peptide vaccines necessarily leads to a more restricted antitumor immune response and hence whole-cell vaccines are also important to develop. Two novel strategies for potentially rendering malignant cells more immunogenic are based on the following techniques: (i) fusion of tumor cells with differentiated autologous DCs to augment presentation of a variety of relevant tumor antigens by 'professional' antigen presenting cells (APCs); 43 and synthetic building of a-Gal epitopes on malignant cells that can then be opsonized by naturally occurring anti-Gal antibody (comprising B1% of circulating IgG in humans) thereby targeting the cells to endogenous APCs. 49, 50 Phase I clinical trials based on these whole-cell vaccine strategies are currently in progress. Direct injection of DCs into tumors has also been used as a mechanism to generate immune responses to potential antigens that are produced by the tumors.
Post-transplant cellular immunotherapy
Even when tumor antigen presentation is optimized, the immune response in the post-transplant setting may be inadequate to control the malignancy as high-dose therapy will deplete the T cell compartment (especially CD4 þ T cells). In addition, potential tumor-reactive T cell populations may be rendered anergic by peripheral (tumorinduced) tolerance mechanisms. Based on studies that showed that signaling through CD3 (component of T cell receptor) and CD28 (receptor for CD86 and CD80 costimulatory molecules) could prevent T cell anergy, 52, 53 techniques for ex vivo expansion and costimulation of autologous T cells have been developed and applied to the clinical setting. 54 A phase I dose escalation study, involving adoptive transfer of up to 1 Â 10 10 costimulated autologous T cells in 16 patients who received CD34 þ -selected autografts for refractory/relapsed non-Hodgkin's lymphoma, showed rapid numeric recovery of lymphocytes, partial reversal of impaired cytokine responsiveness in T cells and a delayed lymphocytosis in five patients, one of whom had concomitant regression of lymphoma. 55 A second study of costimulated autologous T cell infusions following autotransplantation for four patients with interferon or imatinib-resistant CML, described three of four patients who had transient BCR/ABL molecular responses, one of which lasted for more than 4 years post transplant. 56 A multicenter trial of 23 myeloma patients who received 5-10 Â 10 10 ex vivo costimulated autologous T cells on day 3 after autotransplantation also showed robust numeric T cell recovery. 57 In addition, costimulation followed by adoptive transfer partially reversed marked pre-transplant T cell receptor skewing by Vb spectratyping in five patients whose T cells were analyzed both pre-and post-transplant. 57 In the largest study to date of adoptive T cell transfer following autotransplantation, 52 patients with myeloma received a mean dose of 8 Â 10 9 costimulated autologous CD3 þ cells. 58 The T cell infusions were generally well tolerated: 54% of patients had grade I/II chills/rigors, 27% of patients had grade I-III fevers, 12% had grade I-III blood pressure changes and 6% had grade I-III hypoxia which was transient. There were no serious late effects, although 23% of patients developed grade I/II upper body rashes at a median of 13 days post-infusion. Of the 54 total patients who were enrolled in this trial, 42 were randomized to four different treatment groups in which they received costimulated T cells either day 12 or day 100 post transplant and either two or three immunizations using the pneumococcal conjugate vaccine (PCV); the patients who were randomized to three immunizations had the first one prior to T cell collection, in order to prime the T cells in vivo, whereas all patients received booster immunizations at days 30 and 90 post transplant. The patients who were randomized to receive costimulated T cells at day 12 post transplant had significantly higher CD3 þ /CD4 þ counts at days 30, 42 and 90 post-transplant than the patients who did not receive costimulated T cells until day 100. In addition, robust and durable antipneumococcal antibody and vaccine-dependent T cell responses developed only in the group of patients who received three immunizations (one pretransplant þ two post transplant) along with an early (day 12) infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells. This study was the first randomized trial to demonstrate accelerated recovery of CD4 þ T cell numbers and enhanced antigen-specific T cell function post-transplant using a combination of vaccinations and costimulated autologous T cells.
A logical extension of this study will be to test whether in vivo priming of T cells by a putative tumor vaccine followed by early adoptive transfer of ex vivo costimulated, vaccineprimed autologous T cells will lead to development of antitumor immune responses. Two other studies were Whole-cell vaccine with synthetic a-Gal epitopes Utilizes neuraminidase and recombinant alpha 1,3-galactosyl transferase to synthetically build a-Gal epitopes on malignant lymphoma and leukemia cells that can be opsonized by natural, abundant anti-Gal antibody for uptake by APCs 49, 50 conducted based on a similar model. In one study, 22 patients autografted for myeloma were scheduled to receive one pre-transplant and eight post-transplant vaccinations using irradiated autologous myeloma cells admixed with GM-CSF-secreting K562 cells (GVAX, Cell Genesys, San Francisco, CA, USA). 59 In addition, patients received vaccine-primed but resting T cells at the time of stem cell infusion. At 1 year post transplant, 4/10 patients had delayed-type hypersensitivity (DTH) reactions to injections of autologous tumor cells and development of autologous tumor-reactive antibodies was observed in some patients as well. Notably, three patients with rising paraprotein levels early post transplant had subsequent declines after administration of post-transplant vaccines. A study of similar design was conducted in patients with AML. 60 Of 54 patients enrolled in this trial, 27 proceeded to autotransplantation and post-transplant vaccination therapy. DTH reactivity, observed in 43% of patients, was associated with a trend toward longer relapse-free survival and antibody responses to autologous leukemic cells developed in 33% of patients.
Conclusions
High-dose therapy followed by autologous stem cell rescue leads to major tumor cell reductions in the majority of patients who are autografted for hematopoietic neoplasms. However, relapses of disease are common particularly for patients with myeloma or refractory lymphoma. Further progress toward improved event-free and overall survivals after transplant will likely require a multifaceted approach. This approach should include the addition of effective post-transplant immunotherapy and biologically targeted maintenance therapies that are not significantly immunosuppressive nor myelosuppressive. Whereas the post-transplant period may be well suited to the application of immunotherapy because of low disease burden and partial reversal of tumor-induced immune tolerance mechanisms, the depletion of CD4 þ T cell numbers and function which follows high-dose therapy are major impediments. Successful generation of effective post-transplant antitumor immune responses will most likely be based on the following model: (i) identification of subdominant peptides from tumor-associated proteins that bypass central tolerance and can elicit cytotoxic T cell responses in patients; (ii) development of vaccine vehicles for optimal in vivo presentation of one or more tumor antigen peptides or development of high throughput strategies for generating whole-cell vaccines; (iii) in vivo (or possibly ex vivo) priming of autologous T cells by tumor vaccines prior to transplant; (iv) activation and expansion of vaccine-primed T cells by ex vivo costimulation or an equivalent methodology; and (v) early post-transplant adoptive transfer of vaccineprimed and costimulated/expanded T cells followed by a series of booster immunizations.
In regard to post-autograft antimicrobial vaccine coverage, clinicians should administer the 23-valent pneumococcal polysaccharide vaccine at 1-year and 2-years posttransplant as recommended by the ASBMT because about 20-30% of patients do mount protective responses. A safe and effective alternative would be to administer the 7-valent PCV (Prevnar, Wyeth, Collegeville, PA, USA) at 3, 6 and 12 months post-transplant. A series of PCV immunizations should also be administered to patients who develop pneumococcal pneumonia despite earlier vaccination with the standard polysaccharide vaccine or in whom serologic studies demonstrate lack of protective antibody responses. When post-transplant serologic assessments show loss of immunity to tetanus, polio, or diphtheria then a series of three immunizations for these agents should be given. Posttransplant influenza immunizations are also recommended but the likelihood of protection is quite low (B10%).
New insights into the mechanisms behind post-transplant homeostatic T cell expansion also provide an impetus for the exploration of cytokine-based strategies for restoring T cell numbers and function using IL-7 and perhaps IL-15. 23 It is also probable that the strategies that prove successful for restoring immune function following high-dose therapy will be applicable to the growing numbers of individuals who are chronically immunodeficient because of cancer, HIV infection or advanced age. Broader application of these strategies to these vulnerable populations may increase protection against infections, delay or prevent cancer progression, and improve survival.
